Insulin Degludec(Novo Nordisk) success in Nocturnal Hypoglycaemia

Ultra-long-acting insulin degludec, an investigational insulin being developed by Novo Nordisk, significantly reduced the rate of hypoglycaemia at night in adults with Type 2 Diabetes while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period. This phase IIIa study was presented today at the 72nd Scientific Sessions of the American Diabetes Association (ADA).The study also found that insulin degludec had significantly lower rates of severe hypoglycaemia compared to insulin glargine.see Zinman B, et al. The Effect of Insulin Degludec on Glycemic Control and Nocturnal Hypoglycemia Compared with Insulin Glargine: A 1-year Randomized Trial in Insulin-naive People with Type 2 Diabetes. Poster (1047-P) presented at the 72nd Scientific Sessions of the American Diabetes Association, 9 June 2012. (NN1250-3579)Insulin Degludec is filed at EMA and FDA.